INTRODUCTION
Conditionally replicative adenoviruses (CRAds) are designed to specifically target cancer cells by exploiting the very same cellular defects that promote tumor growth. 1 --3 This is generally accomplished by deletion of viral function or insertion of transcriptional regulatory elements to the viral genome. 1 Deletion of the E1B19k, adenoviral homologue of the Bcl-2, was shown to confer cancer selectivity due to genetic defects in apoptotic pathways in cancer cells. 4 Insertion of a heterologous promoter of a tumor-associated marker gene upstream of a key viral transcriptional unit (that is, a viral gene that primes other viral genes) can result in transactivation of viral gene expression by cellular transcription factors that normally regulate the tumor marker. In this manner, expression of the viral transcriptional unit is predicted to occur specifically in tumors that overexpress the marker. 1 The S100 family of proteins is a group of highly conserved elongation factor-hand calcium-binding proteins, with molecular masses in the range of 10 --12 kDa. S100A2, a member of the S100 family of proteins, has been implicated in a variety of cancers. 5 In particular, S100A2 has been proposed as a prognostic marker of tumor progression and/or metastasis in cancers including nonsmall-cell lung carcinoma (NSCLC).
6 --11 S100A2 is a novel transcriptional target of p63/p73 family members (p53 homologues), particularly the p63 splice variant TAp63g. A novel conserved transcriptional element in the S100A2 promoter region is thought to mediate TAp63g-specific regulation. 12 --14 In addition to the regulation by p53 homologues, long-standing evidence suggests that the epidermal growth factor receptor (EGFR) signaling constitutes a major regulatory pathway of S100A2 transcription in human keratinocytes and other epithelial cells. 15 --17 One hypothesis is that increased EGFR signaling may compensate for decreased p53 signaling to maintain S100A2 expression levels in tumor cells, particularly tumors of epithelial cell origin characterized by high levels of autocrine EGF signaling. 16 However, the relationship between S100A2 and EGFR signaling in cancer remains to be demonstrated.
For the current study, we first generated a CRAd vector (Ad/SA) in which the E1A gene is under the control of the S100A2 promoter within an E1B19k-deleted adenoviral backbone, 18 --20 thus creating an S100A2-responsive replicating adenovirus. Here, we demonstrated that the S100A2 promoter-regulated transcription correlates with EGFR signaling in NSCLC-derived cell lines. We also evaluated how this heterologous transcriptional regulatory element inserted within the CRAd genome specifically directs the cell killing of tumors with activated EGFR signaling, thereby reinforcing the inhibitory activity of the virus against tumors. The relationship between S100A2 and EGFR signaling and characterization of the S100A2-driven CRAd in cancer cells, including NSCLC cell lines, was investigated, along with the therapeutic potential of Ad/SA in two experimental mouse tumor models of EGFRactivated human cancers.
RESULTS
Tumor-specific expression of the S100A2 promoter To enable characterization of the promoter, we generated a set of promoter deletion constructs by digestion with several unique restriction endonucleases (Figure 1a) , and then assessed Renilla luciferase gene (Rluc) expression in transiently transfected A-549 cells. Rluc expression was significantly reduced (to 47% that of the native promoter) by the smallest 5 0 deletion (Figure 1b , D167). Promoter deletion analysis also revealed that the S100A2 promoter contains positive regulatory elements in the region spanning nucleotides À1885 to À1640 and negative regulatory elements in the region spanning nucleotides À1640 to À967 (Figures 1a and b) . Both the native S100A2 promoter and the minimal S100A2 promoter (D1918) directed expression of Rluc reporter in all tumor-derived cell lines more than 100-fold than those of human small airway epithelial cells and human embryonic lung fibroblast cells (WI-38; Figure 1c ). The native S100A2 promoter showed 2.5% of luciferase level of the CMV promoter in A-549 cells, which was comparable to that of the E2F-1 promoter, well known for its tumor specificity (Figure 1b) .
Effect of EGFR activation on S100A2 expression and signal activation in NSCLC cells It has been shown that S100A2 was upregulated at the transcription step by EGF signaling in human keratinocytes and other epithelial cells. 15, 16 However, evidence for the same relationship in tumors is insufficient. To test this notion, we prepared a cell panel of NSCLC that commonly overexpresses EGFR and examined whether the S100A2 promoter can be upregulated in this cell panel. As NSCLC is histologically classified as adenocarcinoma, squamous carcinoma, large-cell carcinoma and others, we prepared a cell panel composed of each histological cell type; adenocarcinoma (A-549, NCI-H2009 and -H2228), squamous carcinoma (NCI-H596), large-cell carcinoma (NCI-H460, Calu-6), bronchioalveolar carcinoma (NCI-H358) and unclassified NSCLC (NCI-H2172). As a positive control, A-431 cells, in which the EGFR is constitutively activated, were analyzed in parallel. As a result, EGF treatment induced S100A2 expression, with concomitant increase of the phosphorylated EGFR in the NSCLC cell panel (Figure 2 ). The primary human epithelial cells (small airway epithelial cell and human mammary epithelial cell) and human embryonic lung fibroblasts (WI-38 and MRC5) responded weakly upon EGF stimulation and did not show a minimum detectable change in S100A2 expression. However, the immortalized human keratinocytes (HaCaT), constitutively expressing EGFR, turned on phosphorylation of a great portion of the receptor, and at the same time exhibited slight increase in S100A2 expression in response to EGF. This result was in good agreement with the previous observation that EGF treatment after growth factor deprivation led to a marked increase in S100A2 transcript and protein levels. 15 The degree of increment in S100A2 expression appeared to be marginal in this experiment, but it was attributable to short EGF exposure time comparing with the previous experiments (1 versus 24 h).
Selective killing of tumor cells by the S100A2 promoter-driven adenovirus To explore S100A2 promoter in the construction of CRAd, we generated Rb7D19k and the S100A2 promoter-driven Rb7D19k (Ad/SA). Rb7D19k was designed to carry E1B19k-deleted genome, which allowed a better anti-tumor effect than other E1B gene attenuation, 18 and in addition a pRb-binding mutant E1A (substitution of Glu with Gly at amino acid 45 in the CR1 and seven amino acids (DLTCHEA) with seven Gly (GGGGGGG) in the CR2) for better cancer cell selectivity (Figure 3a) . 19 The innate E1A promoter of Rb7D19k was replaced with the S100A2 promoter in Ad/SA. We then evaluated the cytopathic effect of Ad/SA infection in the cell panel. These viruses were as potent as wild-type (wt) adenovirus in NSCLC cell lines and far more potent than Oncorine, 21 the only CRAd used in clinic. Ad/SA had a significant lytic effect at a multiplicity of infection (MOI) as low as 0.5 in all NSCLC cell lines (Figure 3b ). On the other hand, lysis of normal cells required a much higher titer (MOI of 250), even when the infection was allowed to progress for a few additional days (Figure 3b ). The Rb7D19k virus showed 5-to 20-fold reduced cell killing activity in normal cells, and the Ad/SA virus demonstrated further increased attenuation (25-to 250-fold), compared with wt adenovirus (Figure 3b ). Ad/SA exhibited 100-to 2500-fold greater potency in NSCLC cells as compared with normal cells. Additionally, Ad/SA propagated in 48 h to B15 000 median tissue culture infective dose per cell upon exposure to 5 ng ml À1 or greater EGF, but replicated only to 1000 median tissue culture infective dose per cell with lesser or no EGF (Figure 3c ). The cytolytic activity of Ad/SA was significantly attenuated in the absence of EGF stimulation, but restored to an extent comparable to the Rb7D19k virus in the presence of EGF (Figure 3d and Supplementary Figure  S1 ). Rb7D19k and Ad/SA were almost equivalent to, or more potent than, wt adenovirus in killing tumor cells, whereas these viruses exerted much attenuated killing activity toward normal human cells (Supplementary Figure S1) . In particular, this was noticeable in Ad/SA (Supplementary Figure S1) . These results indicated that the equipment of the S100A2 promoter to control E1A confers an EGF-responsive growth property to the recombinant adenovirus, Ad/SA.
EGF-mediated expression of the S100A2 promoter-driven E1A To investigate the intracellular response to Ad/SA infection and EGF stimulation, we treated serum-starved NCI-H2172 and A-431 cells with varying concentrations of EGF and then infected with Ad/SA. EGF stimulation induced EGFR phosphorylation in 24 h in a dose-dependent manner, whereas EGFR levels remained essentially unchanged in both cell lines (Figures 4a and b) . Ad/SA E1A gene expression increased in an EGF-dependent manner and cellular S100A2 gene expression increased in a similar manner (Figures 4a and b) . The EGFR kinase inhibitor tyrphostin A46 greatly reduced EGFR phosphorylation and S100A2 and E1A gene expression in a dose-dependent manner (Figures 4c and d) . These latter results further support that EGFR signaling leads to transcriptional activation of the S100A2 promoter of the Ad/SA virus.
Several tumor-derived cells and normal human cells were infected with Ad/SA and Rb7D19k, respectively, at different EGF signaling state, that is, EGF signal-stimulating (EGF treated), nonstimulating (starved in serum-free basal medium) and inhibiting (tyrphostin A46 treated) conditions. E1A transcript level significantly increased (by 90% in average) in response to EGF treatment and decreased upon tyrphostin A46 treatment in the Ad/ SA-infected tumor cells, whereas it remained unresponsive to EGF or tyrphostin A46 in the Rb7D19k-infected cells (Supplementary Figure S2 ). In the Ad/SA-infected normal human cells, E1A transcript level was reduced by 81% in average, as compared with that level in the Rb7D19k-infected normal human cells (Supplementary Figure S2 ). Tumor-derived cells exhibited high basal level of E1A transcripts even at serum-starved (EGF signal nonstimulating) condition (Supplementary Figure S2) . This is attributable to typical characteristics of tumor cells, which create and sustain self-activation loop in the signaling system such as EGFR signaling. The level of viral replication significantly increased in the tumor-derived and normal cells (by 11.1-and 2.9-fold in average, respectively) in response to EGF treatment, and decreased (by 79% and 38% in average, respectively) upon tyrphostin A46 treatment, whereas it remained unresponsive to EGF or tyrphostin A46 in the Rb7D19k-and wt adenovirus-infected cells (Supplementary Figure S3) .
Conclusively, these results show that viral replication as well as E1A transcription at the very early stage are greatly associated with cellular EGFR signaling status in the Ad/SA-infected cells, such that Ad/SA becomes more activated in EGFR signal-activated tumor cells but more attenuated in normal cells, as compared with its prototype Rb7D19k or wt adenovirus. Table S1 ), and furthermore three-way combination of Ad/SA with cisplatin and cetuximab exerted 'strong synergism' in NCI-H2172 and A-431 cell lines (Supplementary Table S1 ). These results suggested that Ad/SA combined with standard anti-cancer drugs, such as cisplatin and cetuximab, exerts strong synergism even in cetuximab-resistant tumor cell line. . S100A2 expression and EGFR signal in NSCLC. Serum-starved NSCLC and normal human cells were exposed to 100 ng of EGF in 1 ml of serum-free medium for 1 h, and then harvested to identify EGFR, phospho-EGFR and S100A2 status in the presence or absence of EGF. 3 ) in BALB/c nu/nu mice, based on a previously published protocol, for evaluating cetuximab efficacy. 22 Mice were treated with Ad/SA alone or in combination with a high dose of cisplatin or cetuximab for an extended period of time (Figure 6a ). Mice in the control group reached the experimental end point and were killed on day 16, whereas mice treated with cisplatin alone or cetuximab alone were killed on day 29. Mice that received Ad/SA, either alone or combination with anti-cancer agent, survived until day 36, when they were also killed. All tumors were resected before killing.
Tumor growth in the Ad/SA-alone, cisplatin-alone and cetuximab-alone groups was inhibited by 79%, 54% and 72%, respectively, as observed on day 16 after the first injection (Po0.05 versus Ad-LacZ; Figures 6b and c). Tumor growth arrest was maintained in the Ad/SA-alone group up to the end of the experimental period, whereas tumor size increased steadily up to 3 weeks and even at a higher rate in the cisplatin-alone and cetuximab-alone groups (Figure 6c) . Cetuximab or cisplatin combined with Ad/SA treatment reduced tumor growth by 85% and 82%, respectively (Po0.05 versus Ad-LacZ; Figures 6b and c) . When monitored on days 29 and 36, cetuximab or cisplatin combined with Ad/SA further improved anti-tumor efficacy over either agent alone (Po0.05, cetuximab alone versus cetuximab plus Ad/SA; Po0.05, cisplatin alone versus cisplatin plus Ad/SA; Figures 6b and c) . Ad/SA alone exerted significant anti-tumor activity and combination of cetuximab to this treatment exhibited additional significant improvement (Po0.05, Ad/SA alone versus cetuximab plus Ad/SA; Figures 6b and c) . However, combination of cisplatin to Ad/SA treatment did not demonstrate statistically significant additional effect (P40.05, Ad/SA alone versus cisplatin plus Ad/SA). Anti-cancer activity of Ad/SA was most potent against A-431 tumor xenografts over cisplatin alone or cetuximab alone, and cisplatin, being least active against this tumor xenograft, did not add much to the anti-cancer effect achieved with Ad/SA treatment, as also reflected in the isobologram assay (Supplementary Table S1 ). Of note, in four of the six mice treated Figure S5) , we just applied the cisplatin-alone group or the cetuximab-alone group as a control for two-way combination study. Data represent the means ± s.e., n ¼ 6 per group. (c) Photographs of excised sc NCI-H2172 NSCLC tumors. Mice were killed on day 28.
with cetuximab plus Ad/SA, significant tumor regression was apparent. In two of these mice, the tumor was no longer visible after the last treatment, and in two others tumor growth arrest persisted during the last 4 weeks of the experimental period (Figure 6d ). These results suggested that Ad/SA significantly inhibits the growth of solid tumors in which EGFR signaling is activated, and that combined administration of standard anticancer drugs, such as cisplatin and cetuximab, with Ad/SA significantly improves anti-tumor efficacy.
Ad/SA treatment reduces tumor mass in NCI-H2172-and A-431-derived tumors in vivo Histological analysis indicated a moderate-to-high grade of EGFR expression in most of the cells of tumor section generated from NCI-H2172 and A-431 cell xenografts. Pronounced expression of the adenoviral hexon protein was also noted in the sections of the Ad/SA-treated groups ( Figure 7 and Supplementary Table S2 ). The population of viable tumor cells in hematoxylin and eosinstained tumor sections was greatly reduced in Ad/SA-treated tumors as compared with the control group (Po0.001 and Po0.01 for NCI-H2172 and A-431, respectively; analysis of variance; Figure 7 and Supplementary Table S2 ). Alone, cisplatin or cetuximab had marginal effect on cell viability (P40.05 versus Ad-LacZ), whereas the combination with Ad/SA resulted in a significant reduction in the viable cell population (Po0.001, cisplatin plus Ad/SA versus Ad-LacZ; Po0.01, cisplatin alone versus cisplatin plus Ad/SA; Po0.001, cetuximab plus Ad/SA versus Ad-LacZ; Po0.001, cetuximab alone versus cetuximab plus Ad/SA; Figure 7 and Supplementary Table S2) .
Consistent with the results of histological analysis, terminal deoxynucleotidyl transferase nick-end labeling of tumor sections revealed that there were more apoptotic cells in Ad/SA-treated tumors as compared with controls ( Figure 7) . The apoptosis index, ) A-431 tumor xenografts were randomized into six groups. Each group received three intratumoral injections of Ad-LacZ (*, n ¼ 6) or Ad/SA (J, n ¼ 6) on days 0, 7 and 14, alone or in combination with intraperitoneal injections of cisplatin (&, n ¼ 6) on days 0 and 10, or cetuximab (n, n ¼ 6) twice a week for 4 weeks. Mice that received cisplatin or cetuximab alone were treated intraperitoneally with cisplatin (', n ¼ 5) on days 0 and 10, or cetuximab (m, n ¼ 6) twice a week for 4 weeks. Because Ad-LacZ treatment had no significant influence on cytolytic effect of cisplatin or cetuximab in vitro (Supplementary Figure  S5) , we just applied the cisplatin-alone group or the cetuximab-alone group as a control for two-way combination study. Data represent the means ± s.e. determined by terminal deoxynucleotidyl transferase nick-end labeling staining, was 15-fold higher in the Ad/SA-treated group (Po0.001) than in the control group (Supplementary Table S2 ). Combined administration of cisplatin or cetuximab with Ad/SA further augmented apoptosis in NCI-H2172 tumor sections (Po0.05, cisplatin alone versus cisplatin plus Ad/SA; Po0.01, cetuximab alone versus cetuximab plus Ad/SA; Figure 7 and Supplementary Table S2 ). However, this enhanced effect of combined treatment on apoptosis was not observed in A-431 tumor sections, most likely because of the very limited number of viable cells in these tumors (Supplementary Table S2 ). Collectively, these results suggested that lytic growth of Ad/SA results in tumor cell-specific death, leading to suppression of tumor growth, and that combined administration of standard anti-cancer drugs with Ad/SA results in an additive effect.
Nuclear targets of activated EGFR signaling bind to the S100A2 promoter To identify the molecular mechanism of S100A2 promoter transactivation in response to EGF, we analyzed the sequence of the S100A2 promoter to identify putative binding sites of transcription factors associated with activated EGFR-mediated signaling. Using the TRANSFAC database, we identified putative S100A2 promoter-driven CRAd targets NSCLC K Lee et al binding sites for c-jun/c-fos, Ets-1, Elk-1 and p53 (including p53 homologues) in the S100A2 promoter (data not shown). Other than p53, all of these transcription factors are regarded as nuclear targets of EGFR signaling. 23 To examine whether any of these factors could bind to the S100A2 promoter, we performed an in vitro streptavidin--agarose pull-down assay using a biotin-labeled S100A2 promoter fragment and nuclear lysates of A-431 cells. Immunoblot analysis revealed that c-jun, Ets-1, Elk-1, NFkB and p63 were able to coprecipitate with the S100A2 promoter (Figures 8a and b) . These results provided further support for a transactivation mechanism in which the S100A2 promoter is specifically activated in EGFR signal-activated tumor cells (Figure 8c ). DISCUSSION S100A2 has been implicated in carcinogenesis as both a tumor suppressor and promoter. 5,6,9,24 --27 In a pioneering study of NSCLC cells and tumor specimens, S100A2 was undetectable, leading to speculation that it functions as a novel tumor suppressor. That being said, there is a growing body of evidence suggesting that S100A2 promotes tumor progression. A number of reports have shown that S100A2 is overexpressed in most NSCLC tumor specimens, but is barely detectable in normal lung tissues. 28 --31 Furthermore, overexpression of S100A2 was identified as a potential prognostic marker for poor disease-specific survival in patients with stage I NSCLC and pancreatic cancer. 9, 11 Hypermethylation of the promoter region is a common mechanism of gene silencing. 32 --36 Site-specific DNA methylation of the S100A2 gene promoter in tumorigenic breast cancer cell lines has been shown to correlate with S100A2 repression during breast cancer progression. 32 Likewise, S100A2 methylation and silencing is frequently observed in patients with prostate cancer in an age-dependent manner. 34 Virion DNA is not methylated in productively infected cells; 37 thus, heterologous promoters such as S100A2 that are inserted into the adenoviral genome are protected from methylation. The S100A2 promoterdriven adenovirus system developed here is, therefore, an ideal approach for exploring the tumor-specific potential of the S100A2 promoter.
The role of EGFR signaling in the regulation of S100A2 transcription has been demonstrated mostly in human keratinocytes and other epithelial cells, 15, 16, 38 and the relationship between the EGFR and S100A2 in carcinogenesis remains to be elucidated. S100A2 is believed to be an important mediator of regenerative hyperplasia and the active psoriasis pathway during epidermal differentiation, 15, 16 a process that is triggered by activation of the EGFR signaling pathway. S100A2 transcription is rapidly induced in response to EGF in human keratinocytes, and this increase is blocked by a specific inhibitor of EGFR tyrosine kinase activity. 15 These results was interpreted as suggesting that EGFR activation selectively stimulates S100A2 gene expression at the transcriptional level, and S100A2 belongs to the class of genes associated with cell cycle progression in response to EGF in tissues with high levels of EGFR, such as the cells committed to terminal differentiation. 15, 23 Here, we examined a panel of NSCLC-derived cell lines and showed that, in most of these cells, EGF stimulation gives rise simultaneously to increased levels of phospho-EGFR and S100A2 expression. Sustained activation of the EGFR transduces signals for cell proliferation, anti-apoptosis, angiogenesis and metastases, all of which are hallmarks of cancer. The binding of EGF or tumor growth factor-a to the EGFR results in structural changes in the intracellular domain of the EGFR, leading to activation of its tyrosine kinase domain and receptor autophosphorylation. These early events following ligand binding result in the activation of several intracellular signaling pathways, including the RAS/MAPK, PI3K/Akt and the JAK/STAT pathways. 23 Activation of these signaling pathways culminates in increased levels of transcription factors, such as c-jun/c-fos, Myc, STAT and Ets, 23 which promote the expression of various genes involved in normal and abnormal biological events, including tumorigenesis and metastasis. Therefore, it is reasonable to propose that EGFRmediated activation of S100A2 transcription occurs through elements in the S100A2 promoter region that are targeted specifically in response to EGF. Sequence analysis of the S100A2 promoter and the results of the streptavidin --agarose pull-down assay demonstrated that c-jun/c-fos, Ets-1, Elk-1 and p63 (a p53 homologue) can bind to sites in the S100A2 promoter region, supporting our general hypothesis that S100A2 is a target gene of EGFR-mediated signaling pathways in EGFR-activated cells. In this study, EGFR-mediated activation of S100A2 transcription correlated with transactivation of the S100A2 promoter to control E1A of Ad/SA. The transactivation of the S100A2 promoter by EGF was associated with an increased cytolytic profile of Ad/SA in NSCLC cells. In two EGFR-activated tumor xenograft animal models, Ad/SA exhibited potent anti-tumor activity, whereas cetuximab, an EGFR-targeting anti-cancer drug, was active transiently or ineffective. Of note, cetuximab treatment combined with Ad/SA showed significant additive effect, compared with cetuximab monotherapy.
How did the Ad/SA targeting activated EGFR signal cooperate with this EGFR blocker? Ideally, cetuximab specifically binds to EGFR with a higher affinity than either EGF or tumor growth factor-a, thus blocking ligand-induced phosphorylation of EGFR. In reality, however, perfect blocking of signal transduction seems unattainable, considering the dynamic turnover of EGFR in vivo, which repeats dimerization, dissociation, internalization and translocation, promoting rapid local propagation of the signaling stimulus. 39, 40 In the clinical settings, no studies have been conducted using cetuximab as a single agent in previously untreated patients with advanced NSCLC, 41 and the efficacy of cetuximab plus taxane/carboplatin as first-line treatment of advanced NSCLC has been significant but only partial. 42, 43 Biomarker studies still yet to define the profile of cetuximab sensitivity and resistancy. 44 These collectively suggest that EGFR signal still survives cetuximab treatment in the tumor populations. The additive effect of Ad/SA to cetuximab treatment (Figures 6  and 7) indicates that the EGFR signal surviving cetuximab treatment transactivated the S100A2 promoter of Ad/SA, and thus the counteracting agents, Ad/SA and cetuximab, effectively cooperated to control the heterogenic tumor populations. This notion suggests that Ad/SA treatment may provide an alternative treatment modality for tumors refractory to conventional therapies. Our results also suggest that S100A2 is a target gene of EGFR signaling pathways in epithelial cancers. Continued study will help characterize more fully the functional and clinical importance of S100A2 promoter-associated signaling cascades in normal and cancer settings.
MATERIALS AND METHODS

Cells and cell culture
The human NSCLC cell lines (NCI-H358, -H460, -H596, -H2009, -H2172, -H2228 and Calu-6) and the human epidermal carcinoma cell line A-431 were obtained from the Korean Cell Line Bank (Seoul, Korea). Human embryonic kidney cells (HEK 293); the HeLa (cervical epitheloid carcinoma), HT-29 (colon adenocarcinoma), A-549 (NSCLC) cell lines; and human embryonic lung fibroblasts (MRC-5 and WI-38) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Huh-7 cells (hepatocellular carcinoma) were provided by JCRB (Osaka, Japan). HaCaT (immortalized human keratinocytes) was kindly donated by Professor Sun Yeou Kim (Kyung Hee University, Yongin, Korea). The NSCLC cell lines were cultured in RPMI1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Mediatech, Manassas, VA, USA) and 10 mM HEPES. Small airway epithelial cells and human mammary epithelial cells were provided by Lonza (Walkersville, MD, USA) and cultured according to the manufacturer's recommendation. All other cell lines were maintained in Dulbecco's Modified Eagle's Medium (Invitrogen) supplemented with 10% fetal bovine serum (Mediatech) at 37 1C in a humidified 5% CO 2 atmosphere.
S100A2 promoter and its truncation for reporter assays
The native S100A2 promoter was amplified from genomic DNA isolated from A-549 cells by PCR using ExTaq DNA polymerase (Takara, Otsu, Japan). The sequence of the primers was as follows: forward, 5
0 -CCatcgatTTTGTA-CAGGACAGAACAGGTAGA-3 0 ; reverse, 5 0 -CCaccggtTGGCAGAGACAGACC-CAGGAAG-3 0 (lowercase letters represent the ClaI and AgeI restriction sites). The amplified fragment was inserted into pCR2.1-Topo (Invitrogen) to generate pCR2.1-PS100A2. The DNA sequence of the S100A2 promoter region was confirmed by sequence analysis. 12, 32 For functional analysis of the S100A2 promoter, the native promoter and progressive 5 0 truncation variants (generated by enzyme digestion of pCR2.1-PS100A2 with SpeI, SphI, ClaI, BstEII, AflIII, EcoNI, MscI and StuI) were inserted into the multiple cloning site of phRL-null (Promega, Madison, WI, USA). The variants were designated phRL-S100A2 native, D167, D394, D639, D860, D1312, D1412, D1680 and D1918 based on the size of the truncation. Cells were co-transfected with the various promoter constructs and pcDNA-lacZ using jetPEI (Polyplus-transfection, Illkirch, France). Luciferase activity in the clarified lysates was measured using an RLuc reporter assay kit (Promega) and an LB 96V microplate luminometer (EG&G Berthold, Vilvoorde, Belgium). Luciferase values were normalized to total protein and b-galactosidase activity.
Viruses
The pXC1/DE1B19 (ref. 18) was digested with XbaI/KpnI, and the E1B55k fragment was subcloned into the XbaI/KpnI site of the plasmid pXC1/Mt no. 7 containing the pRb-binding mutant E1A, 19 generating pXC1/Rb7D19. The Rb7D19 gene (mutant E1A and E1B55k) was then excised from pXC1/ Rb7D19 using EcoRI and BamHI, and cloned into pDE1Sp1B to generate pDE1Sp1B/Rb7D19. To generate the pRb-binding mutated and E1B19k-deleted adenovirus, Rb7D19k, PCR-amplified Rb7D19 gene was inserted into the BamHI site of pENTR2B (Invitrogen), generating pENTR-Rb7D19. To generate S100A2 promoter-driven Rb7D19k adenovirus (Ad/SA), the native S100A2 promoter recovered from pCR2.1-PS100A2 digested with ClaI (blunt ended)/AgeI and inserted into the XmnI (blunt ended)/AgeI site located in front of the mutant E1A gene of pENTR-Rb7D19 to generate pENTR-PS100A2-Rb7D19. pENTR-Rb7D19 and pENTR-PS100A2-Rb7D19 were recombined with the E1-deleted adenovirus backbone, pAd/PL-Dest (Invitrogen) in vitro by Clonase (Invitrogen) to generate pAd-Rb7D19 and pAd/SA-Rb7D19, respectively. pAd/PL-Dest also carries a large deletion in E3 sequences from base pairs 28 598 to 40 473. Recombinant adenoviruses, Rb7D19k and Ad/SA, were generated by successive transfection of A-549 cells with the PacI-linearized pAd-Rb7D19 and pAd/SA-Rb7D19, respectively. Homogenous Rb7D19k and Ad/SA viruses were isolated following three sequential rounds of plaque purification. E1B55k-deleted adenovirus, Oncorine (Sunway Biotech, Shanghai, China), wt human adenovirus type 5 (VR-5, ATCC; wt adenovirus) and Ad-LacZ (Invitrogen) were used as reference viruses.
Production, purification and titration of adenoviral vectors HEK 293 cells were grown to a density of 7 --10 Â 10 5 cells ml À1 in a 7 --l Spinferm bioreactor (Braun Biotechnology, Melsungen, Germany) and then infected with Ad/SA at an MOI of 10. Cells were harvested 2 days post infection, and then lysed by a standard freeze --thaw procedure. Ad/SA in the crude lysate was purified by a two-step ion-exchange column chromatography using an Ä kta purifier (GE Healthcare, Uppsala, Sweden). The purified virus was quantified by spectrophotometry for particle concentration (vp) and by a cytopathic end-point dilution assay (median tissue culture infective dose) for infectious titer (iu), according to the standard protocol provided by ARMWG (http://www.isbiotech.org). The quality of purified virus was controlled to o30 vp per iu as recommended by the United States Food and Drug Administration for clinical lots.
Cytopathic effect assay
Cells were seeded in a 48-well plate (1 Â 10 5 cells per well) and incubated overnight. The cells were infected with Ad/SA at varying MOIs ranging from 0.1 to 500. At 7 days (tumor cell lines) or 10 days (normal cells) post infection, cells were stained with crystal violet (100 mg ml À1 in 50% methanol). The plates were washed three times with phosphate-buffered saline, dried and then photographed.
Agarose pull-down assay Nuclear fractions of A-431 cells were prepared using the CelLytic NuCLEAR extraction kit (Sigma, St Louis, MO, USA). A S100A2 promoter fragment was biotinylated at both ends by PCR using a biotin-labeled primer set. A total amount of 1 mg of biotin-labeled DNA was mixed with 100 ml of nuclear extract and 20 ml of streptavidin --agarose (Invitrogen) equilibrated with phosphate-buffered saline. The mixture was incubated with rotation at 4 1C for 1 h and then washed three times with ice-cold phosphate-buffered saline. The pull-down transcription factors were eluted by boiling for 5 min immediately after the addition of 1 Â SDS sample buffer (50 mM Tris-HCl (pH 6.8), 100 mM dithiothreitol, 2% (w/v) SDS, 0.1% bromophenol blue and 10% (w/v) glycerol).
Immunoblot analysis
Samples were resolved by 4 --12% NuPAGE SDS-PAGE (Invitrogen) and then proteins were electro-transferred to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA, USA). Nonspecific binding was blocked by immersing the membrane in Tris-buffered saline-free blocking buffer (Thermo Scientific, Waltham, MA, USA) for 1 h. The membrane was washed three times with Tris-buffered saline containing 0.1% Tween 20 (Sigma) and then incubated with one of the following antibodies, as indicated, at a dilution of 1 : 3000: anti-E1A (BD Pharmingen, San Diego, CA, USA), anti-S100A2 (Sigma), anti-EGFR (R&D Systems, Minneapolis, MN, USA), anti-phospho-EGFR (R&D systems), anti-b-actin (Sigma), anti-Elk1, anti-STAT3, anti-p63 monoclonal antibodies (all from Epitomics, Burlingame, CA, USA), anti-c-Jun (Upstate Biotechnology, Lake Placid, NY, USA) or antiNFkB (Santa Cruz Biotechnology, Santa Cruz, CA, USA) polyclonal antibodies. Following incubation with horseradish peroxidase-conjugated secondary antibody (KPL, Gaithersburg, MD, USA), immunoreactive proteins were detected using an ECL plus detection system (Amersham, Little Chalfont, UK).
Subcutaneous NCI-H2172 and A-431 tumor xenograft studies Animal housing, handling and all procedures involving mice were approved by the institutional committee of MOGAM Biotechnology Research Institute, and all experiments were performed in accordance with the national guideline governing animal care in Korea. NCI-H2172 (5 Â 10 6 ) or A-431 (1 Â 10 7 ) cells were injected subcutaneously into the flanks of six-week-old BALB/c nu/nu mice (SLC, Hamamatsu, Shizuoka, Japan) and then tumor size was measured every 2 --3 days. Tumor volume was determined using the following formula: tumor volume ¼ pab 2 /6, where a ¼ long diameter and b ¼ short diameter. When tumors reached a volume of 50 --100 mm 3 (NCI-H2172) or 400 mm 3 (A-431), mice were randomly grouped. Each group received three intratumoral administrations of Ad-LacZ (1 Â 10 10 vp per injection) as a negative control or Ad/SA on days 0, 7 and 14, either alone or in combination with intraperitoneal injections of cetuximab (1 mg; Merck KGaA, Darmstadt, Germany) or cisplatin (60 mg; Sigma) twice a week for 2 weeks. For large A-431 tumor xenografts, a high dose of cisplatin (150 mg) was given twice (days 0 and 10), and the cetuximab treatment period was extended to 4 weeks, as per a previously published protocol. 21 Moribund mice were killed when the experimental end point (tumor size exceeding 2 cm) was reached.
Histology and immunohistochemistry
Tumor specimens were dissected from mice and fixed in a 3.8% neutralized formalin solution (Sigma) overnight. Specimens were embedded in paraffin and then cut into 4-mm sections. Hematoxylin and eosin staining and terminal deoxynucleotidyl transferase nick-end labeling staining were performed according to the procedure described previously. 45 For adenovirus detection, paraffin sections were deparaffinized with xylene and then incubated with a monoclonal antibody (1:100 dilution) against adenovirus type 5 hexon (Chemicon International, Temecula, CA, USA) before counterstaining with hematoxylin. For EGFR immunohistochemistry, the sections were stained using an EGFR PharmDx immunohistochemical kit (DakoCytomation; Carpinteria, CA, USA) according to the manufacturer's instructions. Slides were counterstained with hematoxylin, dehydrated, mounted and then viewed under a fluorescence microscope (Olympus, Tokyo, Japan). Each staining run was validated according to the manufacturer's procedure (DakoCytomation).
Statistical analysis
Results were subjected to statistical analysis using GraphPad Prism version 5.0 software (GraphPad Software, San Diego, CA, USA). Repeated-measure analysis of variance was followed by Tukey's multiple comparison test. Student's t-tests were two tailed. A P-value of o0.05 was considered statistically significant.
